Prevalence of CDKN2A mutations in pancreatic cancer patients: Implications for genetic counseling

European Journal of Human Genetics

Volumn 19, Issue 4, 2011, Pages 472-478

  McWilliams, Robert R ^a   Wieben, Eric D ^b   Rabe, Kari G ^a   Pedersen, Katrina S ^a   Wu, Yanhong ^b   Sicotte, Hugues ^a   Petersen, Gloria M ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

cyclin dependent kinase inhibitor p16; genes; p16; pancreatic neoplasms

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GERM LINE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATION RATE; PANCREAS ADENOCARCINOMA; PENETRANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PENETRANCE; PREVALENCE; SKIN NEOPLASMS; SMOKING;

NICOTIANA TABACUM;

EID: 79952742260     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2010.198     Document Type: Article

References (40)

1. Lynch HT, Krush AJ: Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J 1968; 99: 17-21
2. Goldstein AM, Fraser MC, Struewing JP et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. New Engl J Med 1995; 333: 970-974
3. Bartsch DK, Sina-Frey M, Lang S et al: CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 2002; 236: 730-737 (Pubitemid 35403228)
4. Lynch HT, Brand RE, Hogg D et al: Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinomaprone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002; 94: 84-96 (Pubitemid 34049045)
5. Schutte M, Hruban RH, Geradts J et al: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130 (Pubitemid 27351723)
6. Jing F, Zhang J, Tao J et al: Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie 2007; 30: 14-19 (Pubitemid 46175615)
7. Debniak T, Gorski B, Huzarski T et al: A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 2005; 42: 763-765 (Pubitemid 41475251)
8. de Snoo FA, Bishop DT, Bergman Wet al: Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008; 14: 7151-7157
9. Bahuau M, Vidaud D, Jenkins RB et al: Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998; 58: 2298-2303 (Pubitemid 28252682)
10. Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET: Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst 1996; 88: 1489-1491 (Pubitemid 26340052)
11. Lukas J, Parry D, Aagaard L et al: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503-506
12. Debniak Ta, van de Wetering Ta, Scott Re et al: Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. Eur J Cancer Prev 2008; 17: 389-391
13. Ghiorzo P, Pastorino L, Bonelli L et al: INK4/ARF germline alterations in pancreatic cancer patients. Ann Oncol 2004; 15: 70-78 (Pubitemid 38139606)
14. Vasen HFA, Gruis NA, Frants RR, van der Velden PA, Hille ETM, Bergman W: Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87: 809-811 (Pubitemid 30660559)
15. McWilliams RR, Bamlet WR, de Andrade M, Rider DN, Cunningham JM, Petersen GM: Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L. Cancer Epidemiol Biomarkers Prev 2009; 18: 1295-1302
16. Nickerson DA, Tobe VO, Taylor SL: PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25: 2745-2751 (Pubitemid 27299787)
17. Agresti A: Categorical Data Analysis, 2nd edn, John Wiley & Sons: Hoboken, NJ, 2002
18. Chatterjee N, Wacholder S: A marginal likelihood approach for estimating penetrance from kin-cohort designs. Biometrics 2001; 57: 245-252 (Pubitemid 32200163)
19. Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J: CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 2000; 60: 6864-6867 (Pubitemid 32059154)
20. Goldstein AM, Stacey SN, Olafsson JH et al: CDKN2A mutations and melanoma risk in the Icelandic population. J Med Gen 2008; 45: 284-289 (Pubitemid 351685146)
21. Spica T, Portela M, Gerard B et al: The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol 2006; 126: 1657-1660
22. Hussussian CJ, Struewing JP, Goldstein AM et al: Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15-21 (Pubitemid 24274055)
23. Kamb A, Shattuck-Eidens D, Eeles R et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8: 23-26
24. Pjanova D, Engele L, Randerson-Moor JA et al: CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res 2007; 17: 185-191 (Pubitemid 46788103)
25. Goldstein AM, Chan M, Harland M et al: High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66: 9818-9828 (Pubitemid 44672032)
26. Begg CB, Orlow I, Hummer AJ et al: Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005; 97: 1507-1515 (Pubitemid 41631950)
27. Ghiorzo P, Gargiulo S, Nasti S et al: Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy. J Clin Oncol 2007; 25: 5336-5337 (Pubitemid 350232278)
28. Orlow I, Roy P, Barz A, Canchola R, Song Y, Berwick M: Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of human INK4A gene mutations. J Mol Diagn 2001; 3: 158-163 (Pubitemid 33100336)
29. Goldstein AM: Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004; 23: 630
30. Rutter JL, Goldstein AM, Davila MR, Tucker MA, Struewing JP: CDKN2A point mutations D153spl(c.457G4T) and IVS2+1G4T result in aberrant splice products affecting both p16INK4a and p14ARF. Oncogene 2003; 22: 4444-4448 (Pubitemid 36897975)
31. Liu L, Dilworth D, Gao L et al: Mutation of the CDKN2A 5¢ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 1999; 21: 128-132 (Pubitemid 29036299)
32. Debniak T, Scott RJ, Huzarski T et al: CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005; 65: 835-839 (Pubitemid 40216442)
33. Lynch HT, Brand RE, Hogg D et al: Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinomaprone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002; 94: 84-96 (Pubitemid 34049045)
34. Borg A, Sandberg T, Nilsson K et al: High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92: 1260-1266 (Pubitemid 30627734)
35. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA: Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet 2004; 41: 421-424 (Pubitemid 38788036)
36. Leachman SA, Carucci J, Kohlmann W et al: Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad of Dermatol 2009; 61: 677.e1-677.e14
37. Hansen CB, Wadge LM, Lowstuter K, Boucher K, Leachman SA: Clinical germline genetic testing for melanoma. Lancet Oncol 2004; 5: 314-319 (Pubitemid 38541583)
38. Mantelli M, Barile M, Ciotti P et al: High prevalence of the G101W germline mutation in the CDKN2A (P16/ink4a) gene in 62 Italian malignant melanoma families. Am J Med Genet 2002; 107: 214-221 (Pubitemid 34044893)
39. Silverman DT, Dunn JA, Hoover RN et al: Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994; 86: 1510-1516 (Pubitemid 24330214)
40. Fuchs CS, Colditz GA, Stampfer MJ et al: A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996; 156: 2255-2260. (Pubitemid 26361920)